tremor/seizures

BACKGROUND OF THE INVENTION 1. Field of Invention This invention relates to treatment of human beings for conditions associated with deficiencies in the N-6-trimethyl-L-lysine (TML) pathway affecting biosynthesis of carnitine. Such conditions include: (1) seizures, myoclonic seizures, epilepsy,

FIELD OF THE INVENTION Aspects of the present invention relate generally to alcohol withdrawal syndrome (AWS), and isoprenoid-based compounds, and more particularly to pharmaceutical compositions comprising calcium channel blockers (e.g., isoprenoids such as farnesol and/or farnesol analogues or

BACKGROUND OF THE INVENTION This invention relates to seizure monitors, and more particularly relates to means for monitoring movements attributable to seizures and convulsions of patients having epilepsy or other seizure disorders. As is well known by those skilled in the art, it is common practice

FIELD OF THE INVENTION The present invention relates to a method of treating convulsions, including convulsive tremors and convulsive seizures, and, in particular, epilepsy, with organic copper compounds. BACKGROUND OF THE INVENTION Copper is a normal component of the human brain, which contains

FIELD OF THE INVENTION The present invention relates to a method of treating convulsions, including convulsive tremors and convulsive seizures, and, in particular, epilepsy, with organic copper compounds. BACKGROUND OF THE INVENTION Copper is a normal component of the human brain, which contains

FIELD OF THE INVENTION The present invention relates to a method of convulsions, including convulsive tremors and convulsive seizures, and, in particular, epilepsy, with organic copper compounds. BACKGROUND OF THE INVENTION Copper is a normal component of the human brain, which contains about 370 mg

FIELD OF THE INVENTION The present invention relates to a method of treating convulsions, including convulsive tremors and convulsive seizures, and, in particular, epilepsy, with organic copper compounds. BACKGROUND OF THE INVENTION Copper is a normal component of the human brain, which contains

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT Not applicable INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC Not applicable BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates generally to medical equipment for Magnetic Resonance Therapy

TECHNICAL FIELD Methods of treating developmental disorders with biguanides are provided. BACKGROUND Biguanides such as metformin, buformin and phenformin have been used as antihyperglycemic agents in the treatment of diabetes. Metformin decreases hepatic glucose production, decreases intestinal

TECHNICAL FIELD Methods of treating developmental disorders with biguanides are provided. BACKGROUND Biguanides such as metformin, buformin and phenformin have been used as antihyperglycemic agents in the treatment of diabetes. Metformin decreases hepatic glucose production, decreases intestinal

BACKGROUND OF THE INVENTION In man, the nervous system responds markedly to certain sensory signals in a narrow band of frequencies near 1/2 Hz; the response to the sensory signals includes sleepiness, drowsiness, relaxation, a tonic smile, ptosis of the eyelids, the feeling of a "knot" in the

BACKGROUND OF THE INVENTION The invention relates to influencing the nervous system of a subject by pulsative stimulation of sensory receptors, relying on the mechanisms of sensory resonance and frequency modulation of spontaneous spike patterns, as discussed in U.S. Pat. No. 5,782,874. [1]. In that

FIELD OF THE INVENTION This invention relates to compounds having beneficial effects in the central nervous system (CNS) of mammals. More specifically, this invention relates to compounds that prevent or halt ongoing seizures in mammals, and thus have antiepileptic/anticonvulsant activities that are

CROSS REFERENCE TO RELATED APPLICATIONS This application is a National Stage of International Application No. PCT/JP2011/067394 filed Jul. 29, 2011, claiming priority based on Japanese Patent Application No. 2010-170732 filed Jul. 29, 2010, the contents of all of which are incorporated herein by

CROSS REFERENCE TO RELATED APPLICATIONS This is a National Stage of International Application No. PCT/JP2009/067441 filed Sep. 30, 2009, claiming priority based on Japanese Patent Application No. 2008-257072 filed Oct. 2, 2008, the contents of all of which are incorporated herein by reference in